Generalized Anxiety Disorder

Generalized Anxiety Disorder (GAD) is characterised by excessive anxiety and worry about a number of events or activities (e.g., work, health, family, finances), occurring more days than not for at least 6 months. The worry is difficult to control and is associated with restlessness, fatigue, concentration problems, irritability, muscle tension, or sleep disturbance. DSM-5-TR classifies GAD under Anxiety Disorders. References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Generalized Anxiety Disorder (GAD) is characterised by excessive anxiety and worry about a number of events or activities (e.g., work, health, family, finances), occurring more days than not for at least 6 months. The worry is difficult to control and is associated with restlessness, fatigue, concentration problems, irritability, muscle tension, or sleep disturbance. DSM-5-TR classifies GAD under Anxiety Disorders. It is common, often chronic, and frequently comorbid with depression and other anxiety disorders. This document is for psychoeducation only.

Excessive worry about multiple domains (work, health, family, money, minor matters); worry is difficult to control; worry occurs more days than not for at least 6 months. Associated symptoms (at least 3): restlessness or feeling keyed up or on edge; being easily fatigued; difficulty concentrating or mind going blank; irritability; muscle tension; sleep disturbance (difficulty falling or staying asleep, restless sleep). The anxiety and worry cause significant distress or impairment and are not confined to another disorder (e.g., panic, social anxiety, OCD).

Genetic: heritability about 30%; family history of anxiety and depression. Temperament: behavioural inhibition, neuroticism. Environmental: overprotective parenting, childhood adversity, stressful life events. Female sex (about 2:1). Often begins in adolescence or early adulthood.

Neurobiological: amygdala and anterior cingulate hyperactivity; reduced GABA and serotonin tone. Cognitive: intolerance of uncertainty; attentional bias toward threat; positive beliefs about worry. Learning: worry may be reinforced by short-term reduction of uncertainty.

Lifetime prevalence about 5-6%; 12-month about 2-3%. One of the most common anxiety disorders. High comorbidity: MDD (about 50%), other anxiety disorders, substance use. Chronic course; often waxing and waning.

Functional imaging: increased amygdala and insula activation to threat; altered prefrontal-amygdala connectivity. Neurotransmitter: serotonin, norepinephrine, and GABA are implicated; benzodiazepines and SSRIs are both effective. The amygdala (threat detection) reacts more strongly to uncertain or negative situations; the prefrontal cortex (which normally helps regulate worry) does not effectively dampen this response. Reduced GABA (calming) and serotonin tone contribute to persistent anxiety and tension. CBT and SSRIs strengthen top-down regulation and rebalance neurotransmitters. Per StatPearls/NCBI, the neurobiology reflects altered threat processing and regulation rather than a character flaw.

Clinical interview: domains of worry; controllability; duration; associated somatic and cognitive symptoms. GAD-7 (7-item self-report) for screening and severity. Rule out medical causes (hyperthyroidism, cardiac, caffeine, stimulants). Screen for depression (PHQ-9) and other anxiety disorders.

DSM-5-TR: A. Excessive anxiety and worry about a number of events or activities, occurring more days than not for at least 6 months. B. Worry is difficult to control. C. Anxiety and worry associated with at least 3 of: restlessness, fatigue, concentration problems, irritability, muscle tension, sleep disturbance. D. Significant distress or impairment. E. Not attributable to substance or medical condition. F. Not better explained by another mental disorder.

GAD-7 (cutoff 10 or more); Penn State Worry Questionnaire (PSWQ); MINI or SCID-5 for structured diagnosis. Comorbidity assessment; medical workup as indicated.

Normal worry: proportional, controllable, not impairing. MDD: worry may be secondary to depression; if both present, both may be diagnosed. Panic disorder: worry focused on panic attacks. Social anxiety: worry about social evaluation. OCD: obsessions are more intrusive and linked to compulsions. Medical: hyperthyroidism, pheochromocytoma, caffeine or stimulant use.

Psychotherapy: CBT is first-line; targets worry, intolerance of uncertainty, and avoidance. Pharmacotherapy: SSRIs (sertraline, escitalopram) and SNRIs (venlafaxine, duloxetine) are first-line; FDA-approved for GAD. Benzodiazepines: short-term use only (risk of dependence, cognitive effects). Buspirone: alternative with less abuse potential. Combination of CBT and medication is often more effective than either alone.

Relaxation and mindfulness as adjuncts.

Chronic but treatable; many improve with CBT and/or medication. Residual symptoms common; relapse possible after discontinuation. Comorbid depression worsens prognosis.

Functional impairment: GAD affects work performance, relationships, and decision-making; chronic worry can paralyse planning and reduce quality of life. Increased healthcare utilisation: somatic symptoms (chest tightness, GI upset, headaches) drive repeated medical visits before the anxiety disorder is recognised. Cardiovascular: chronic anxiety and stress contribute to hypertension and cardiovascular risk over time. Gastrointestinal: irritable bowel syndrome and functional GI complaints commonly co-occur. Insomnia: difficulty falling or staying asleep is both a symptom and a perpetuating factor. Depression develops in approximately 50% of those with GAD; the combination worsens prognosis. Substance use: alcohol and benzodiazepines are often used for self-medication, risking dependence. Suicidal ideation increases when GAD is comorbid with depression.

No proven primary prevention; early intervention when worry becomes impairing can limit chronicity. Stress management, regular exercise, and adequate sleep reduce vulnerability. Limiting caffeine and alcohol improves anxiety and sleep. Patient education: GAD is a treatable brain-based condition, not a character flaw. Worry does not prevent bad outcomes—it only consumes mental energy and maintains anxiety. CBT and medication are both effective; many patients benefit from the combination. Learning to tolerate uncertainty (rather than trying to eliminate it through worry) is a core treatment goal. Families can help by not accommodating avoidance and by supporting treatment engagement.

Generalised anxiety and "anxiety neurosis" appeared in earlier classifications. DSM-III-R (1987) formalised GAD with specific criteria: excessive worry about multiple life domains for at least 6 months. DSM-IV and DSM-5-TR refined the criteria. Treatment guidelines have shifted from benzodiazepines (effective but with dependence risk) to SSRIs and SNRIs as first-line pharmacotherapy, with CBT as the first-line psychosocial treatment. The intolerance-of-uncertainty model and metacognitive theory have refined our understanding of why people worry and how to target it therapeutically.

GAD is often underrecognised as "just worrying" or "being a worrier"—yet it carries substantial burden and disability. Many individuals do not seek treatment because they believe worry is normal or that nothing can help. Stigma around mental health may prevent treatment-seeking. Primary care is often the first point of contact; screening tools (GAD-7) can improve detection. Culturally, the threshold for "excessive" worry varies; somatic presentation may predominate in some groups. Workplace and family roles may normalise chronic anxiety; education about GAD as a treatable condition can encourage

help-seeking.

Neuroimaging biomarkers; intolerance of uncertainty and metacognitive models; digital and brief interventions; combination and sequencing of CBT and medication.

APA. (2022). DSM-5-TR. APA Publishing. Sadock BJ, et al. (Eds.). (2024). Kaplan and Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls. GAD. NCBI Bookshelf.

NIMH GAD: https://www.nimh.nih.gov/health/topics/generalized-anxiety-disorder-gad StatPearls: https://www.ncbi.nlm.nih.gov/books/NBK441870/ Note: Educational only. Not a substitute for professional care.